Researchers from the University of Illinois Urbana-Champaign have made a significant breakthrough in Alzheimer’s disease research by identifying the earliest-yet biomarker for the condition. The neural-specific protein, PSD-95, was found to surge in the brain, indicating the earliest stages of Alzheimer’s disease. This protein plays a crucial role in attracting and pulling other receptors to the synaptic surface, where two neurons pass signals to one another. The increased activity of PSD-95 leads to seizures associated with the earliest stages of neurodegeneration.
Biomarker for Alzheimer’s Disease
The researchers found that the neural-specific protein, PSD-95, surges in the brain, indicating the earliest stages of Alzheimer’s disease. This protein plays a crucial role in attracting and pulling other receptors to the synaptic surface, where two neurons pass signals to one another. The increased activity of PSD-95 leads to seizures associated with the earliest stages of neurodegeneration.